NCT06170294 is a Phase 1 clinical trial of TCR-MAGE-A4 T-Cells in Advanced Solid Tumor, sponsored by Peking University.

Who is sponsoring NCT06170294?

NCT06170294 is sponsored by Peking University.

What drugs are being tested in NCT06170294?

Interventions in NCT06170294: TCR-MAGE-A4 T-Cells.

What condition does NCT06170294 study?

NCT06170294 studies Advanced Solid Tumor.

Is NCT06170294 still recruiting?

NCT06170294 is currently recruiting now. Last updated 14 December 2023.

Last reviewed 2023-12-14 · How we verify

NCT06170294

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Recruiting now Phase 1 Last updated 14 December 2023

What this trial tests

Phase 1 trial testing TCR-MAGE-A4 T-Cells in Advanced Solid Tumor in 20 participants. Currently enrolling.

Timeline

1 January 2024

Primary endpoint
31 December 2025

31 December 2028

Quick facts

Lead sponsor	Peking University
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 January 2024
Primary completion	31 December 2025
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

TCR-MAGE-A4 T-Cells — full drug profile →

Conditions studied

Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Peking University

Who can join

Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.
Knafler G, Ho AL, Moore KN, Pollack SM, et al · · 2025 · cited 6× · PMID 39970827 · DOI 10.1016/j.ctrv.2025.102891
Exploring the role and mechanisms of MAGEA4 in tumorigenesis, regulation, and immunotherapy.
Zhu W, Yi Q, Chen Z, Wang J, et al · · 2025 · cited 4× · PMID 39905312 · DOI 10.1186/s10020-025-01079-8

Verify or expand the search:

Other recruiting trials for Advanced Solid Tumor

Currently open trials in the same condition.

NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting

Other Peking University trials

Trials by the same sponsor.

NCT07519122 — Fangshan Active Nutrition Initiative · NA · not yet recruiting
NCT07466238 — HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer · NA · recruiting
NCT07480525 — Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder · NA · not yet recruiting
NCT07454031 — Intraperitoneal PX in Combination With Nab-Paclitaxel in Patients With Peritoneal Metastatic Mucinous Adenocarcinoma · Phase 1 · not yet recruiting
NCT07466225 — HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06170294 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University
Last refreshed: 14 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06170294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing